SA国际传媒

Any startup CEO can talk about future plans for going public. But until a company actually files for an IPO, it鈥檚 all just speculation.

We鈥檙e not talking about confidential filings either. Sure, they signal serious intent and contain valuable information for regulators. But for the rest of us, it鈥檚 the public S-1 filing that signifies an IPO is actually imminent.

By this latter measure, the past few weeks have been pretty busy for venture-backed startups. , the designer of speedy AI inference chips, filed publicly last week for an offering expected to raise around $2 billion. The Silicon Valley company, which withdrew plans for an IPO last fall, is reportedly seeking a valuation upwards of $35 billion this time around.

That alone would be enough to set IPO market watchers abuzz. Per SA国际传媒 data, it stands to be the largest initial share offering of a U.S. semiconductor company to date.

However, Cerebras wasn鈥檛 the only venture-backed company seeking a multibillion-dollar IPO valuation.

Power players

Another, albeit smaller, contender is nuclear power startup , which is on the cusp of making its debut. It set a price range for shares this week at a target valuation of up to $7.5 billion. The Rockville, Maryland-based company, which makes small nuclear reactors, is hoping to raise over $800 million in the offering.

Meanwhile, on the geothermal power front, is also looking to take its clean energy ambitions to the public market. The Houston-based company filed last week for a offering that could bring in around $250 million.

Biotech IPOs heating up

Biotech is also heating up. Last week delivered a big debut from , a Waltham, Massachusetts-based developer of oral and injectable treatments for obesity and metabolic disease that $718 million in its Nasdaq offering. , a Fremont, California-based startup applying proteomics to early disease detection, made its market entry as well, securing a current market cap around $1.6 billion.

More biotech debuts are on deck too. Austin-based , a venture-backed developer of a nerve stimulation device for stroke survivors, filed last week for an offering. The prior week brought S-1 filings from Boston鈥檚 , a developer of medicines for depression, anxiety and other neuropsychiatric disorders, and , a Denmark-based biotech which focuses on treatment of blood coagulation disorders.

Space and defense on the rise

Of course, everyone knows the Texas-based company on deck to publicly file for a space tech offering of unprecedented magnitude. for an IPO a few weeks ago, with media reports pegging its target valuation around $1.75 trillion. If the company forges ahead with reported plans for a June market debut, a public filing should follow in the next few weeks.

In the interim, another, much, much smaller offering in the defense tech space is on track to hit the market much sooner. , a Herndon, Virginia-based developer of radio frequency intelligence for military customers, filed earlier this month for a offering. It comes amid a period of heightened investor appetite for defense tech, with an expectation of more debuts in the space likely in coming months.

Now we just need some software

Of course, it鈥檚 not an IPO market that is welcoming to all venture-backed startup sectors. One area noticeably absent from the impending offering list is enterprise software. While SaaS has long been a mainstay of the IPO pipeline, the sector has taken a hit of late amid investors’ concerns of AI disruption.

That said, it鈥檚 still encouraging to see a swathe of other sectors dipping a toe in IPO waters.

Related SA国际传媒 queries:

Related reading:

• After Swarmer鈥檚 Soaring Debut, Here Are 12 Other Potential Defense Tech IPOs
• IPOs Are Holding Up In 2026, But SaaS Debuts Aren鈥檛 Happening

Illustration: